ACRV Historical PE Ratio image Acrivon Therapeutics Historical PE Ratio

This ACRV historical PE ratio page, which was last updated 11/10/2026, presents historical price to earnings information for Acrivon Therapeutics under both the TTM method and the annualized method, and presented in both tabular and graphical format for ease of study.

ACRV Historical PE Ratio Notes

— Acrivon Therapeutics (ticker symbol: ACRV) is a clinical-stage biopharmaceutical company focused on developing precision oncology drugs designed to match each patient’s tumor profile using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform. This technology enables Acrivon to identify patients most likely to benefit from its lead therapies, potentially improving clinical outcomes. For investors reviewing ACRV’s historical price-to-earnings (PE) ratio, it’s essential to note that, like many early-stage biotech firms, Acrivon has not historically generated positive earnings due to continual research & development costs and its lack of marketed products. This typically results in negative or undefined PE ratios, as the company is pre-revenue and reports net losses. The market values ACRV primarily on future potential rather than current profitability, so fluctuations in the historical price and PE ratio often reflect sentiment around clinical trial progress, regulatory milestones, & partnership announcements rather than stable earnings trends. When reviewing historical PE ratios for ACRV, consider that changes are likely driven more by expectations for clinical success than by shifts in current or trailing earnings.
ACRV Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q2 2026
8/12/2026
1.72-0.43-1.72NA
Q1 2026
5/13/2026
1.92-0.49-1.96NA
Q4 2025
3/19/2026
1.70-0.49-1.96NA
Q3 2025
11/13/2025
2.07-0.47-1.88NA
Q2 2025
8/13/2025
1.31-0.55-2.20NA
Q1 2025
5/14/2025
1.14-0.51-2.04NA
Q4 2024
3/27/2025
2.52-0.60-2.40NA
Q3 2024
11/13/2024
7.93-0.59-2.36NA
Q2 2024
8/13/2024
7.25-0.52-2.08NA
Q1 2024
5/14/2024
8.36-0.73-2.92NA
Q4 2023
3/28/2024
7.15-0.86-3.44NA
Q3 2023
11/9/2023
4.59-0.66-2.64NA
Q2 2023
8/11/2023
12.39-0.63-2.52NA
Q1 2023
5/9/2023
13.57-0.58-2.32NA
Q4 2022
3/28/2023
13.40-0.80-3.20NA
Q3 2022
12/15/2022
11.52-5.17-20.68NA
ACRV PE History Chart
PeriodPriceGAAPTTMPE
Q2 2026
8/12/2026
1.72-0.43-1.88NA
Q1 2026
5/13/2026
1.92-0.49-2.00NA
Q4 2025
3/19/2026
1.70-0.49-2.02NA
Q3 2025
11/13/2025
2.07-0.47-1.53NA
Q2 2025
8/13/2025
1.31-0.55-1.66NA
Q1 2025
5/14/2025
1.14-0.51-1.70NA
Q4 2024
3/27/2025
2.52-0.60-2.44NA
Q3 2024
11/13/2024
7.93-0.59-2.70NA
Q2 2024
8/13/2024
7.25-0.52-2.11NA
Q1 2024
5/14/2024
8.36-0.73-2.25NA
Q4 2023
3/28/2024
7.15-0.86-2.15NA
Q3 2023
11/9/2023
4.59-0.66-2.67NA
Q2 2023
8/11/2023
12.39-0.63-7.18NA
Q1 2023
5/9/2023
13.57-0.58NANA
Q4 2022
3/28/2023
13.40-0.80NANA
Q3 2022
12/15/2022
11.52-5.17NANA
Quotes delayed 20 minutes

Email EnvelopeFree ACRV Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Acrivon Therapeutics (ACRV) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

ACRX Historical PE Ratio
ACTU Historical PE Ratio
ACXP Historical PE Ratio
ADGI Historical PE Ratio
ADIL Historical PE Ratio
ADMA Historical PE Ratio
ADMP Historical PE Ratio
ADMS Historical PE Ratio
ADPT Historical PE Ratio
ADTX Historical PE Ratio
How should the ACRV historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Acrivon Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this ACRV Historical PE Ratio page.

What is the average historical PE for ACRV based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The ACRV historical PE ratio using the annualized quarterly earnings method works out to NA.

What is the average historical PE for ACRV based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The ACRV historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the ACRV Historical PE Ratio information for Acrivon Therapeutics' stock. The average ACRV historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ACRV historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ACRV historical PE result, against the recent PE: when this page was posted on 11/9/2026, the most recent closing price for ACRV had been 1.58, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on ACRV or any other given stock, valuation analysis for ACRV can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Acrivon Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ACRV. Thanks for visiting, and the next time you need to research ACRV Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.
 

ACRV Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2026, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.